Abstract:Alveolar echinococcosis (AE) is a chronic and fatal infectious parasitic disease, which has not been well-researched. Current recommended therapies for AE by the World Health Organization include complete removal of the infected tissue followed by two years of albendazole (ABZ), administered orally, which is the only effective first-line anti-AE drug. Unfortunately, in most cases, complete resection of AE lesions is impossible, requiring ABZ administration for even longer periods. Only one-third of patients experienced complete remission or cure with such treatments, primarily due to ABZ's low solubility and low bioavailability. To improve ABZ bioavailability, albendazole bile acid derivative (ABZ-BA) has been designed and synthesized. Its structure was identified by mass spectrometry and nuclear magnetic resonance. Its physicochemical properties were evaluated by wide-angle X-ray diffraction, differential scanning calorimetry, scanning electron microscopy, and polarizing microscopy; it was compared with ABZ to assess its solubilization mechanism at the molecular level. To avoid the effects of bile acid on the efficacy of albendazole, the inhibitory effect of ABZ-BA on protoscolex (PSCs)s was observed in vitro . The inhibitory effect of ABZ-BA on PSCs was evaluated by survival rate, ultrastructural changes, and the expression of key cytokines during PSC apoptosis. The results showed that ABZ-BA with 4-amino-1-butanol as a linker was successfully prepared. Physicochemical characterization demonstrated that the molecular arrangement of ABZ-BA presents a short-range disordered amorphous state, which changes the drug morphology compared with crystalline ABZ. The equilibrium solubility of ABZ-BA was 4-fold higher than ABZ in vitro . ABZ-BA relative bioavailability (F rel ) in Sprague-Dawley (SD) rats was 26-fold higher than ABZ in vivo . The inhibitory effect of ABZ-BA on PSCs was identical to that of ABZ, indicating that adding bile acid did not affect the efficacy of anti-echinococcosis. In the pharmacodynamics study, it was found that the ABZ-BA group had 2.7-fold greater than that of Albenda after 1 month of oral administration. The relative bioavailability of ABZ-BA is significantly better than ABZ due to the transformation of the physical state from a crystalline state to an amorphous state. Furthermore, sodium-dependent bile acid transporter (ASBT) expressed in the apical small intestine has a synergistic effect through the effective transport of bile acids. Therefore, we concluded that the NC formulation could potentially be developed to improve anti-AE drug therapy. Alveolar echinococcosis (AE) is a neglected zoonotic parasitic disease caused by Echinococcus multilocularis ( E . multilocularis ). This parasitic infection can cause severe damage to the liver, lungs, and other human or animal organs, which can be fatal if left untreated. The 10-year mortality rate for patients with untreated or improperly treated AE is greater than 90%. Therefore, AE is also called as "worm cancer". Benzimidazoles, including the first-line drug ABZ, are considered the only effective drug against AE. However, ABZ has a low and erratic oral bioavailability due to its low solubility,which has partially led to unsatisfactory clinical efficacy of this oral drug. In this study, albendazole bile acid derivatives were prepared to improve the anti- Echinococcus multilocularis effect. The synergistic effect of steric hindrance and transmembrane transport increased the equilibrium solubility of ABZ-BA in vitro by nearly 4-fold and the bioavailability in vivo by about 90-fold. The in vivo study demonstrated that the pharmacokinetic behavior of the ABZ-BA was superior to that of Albenda. In the pharmacodynamics study, it was also found that the ABZ-BA group had a significant therapeutic effect after 1 month of oral administration. This albendazole bile acid derivative provides an effective and translatable novel approach to oral drug therapy for chronic, fatal, and neglected parasitic infectious alveolar echinococcosis.

Polarization modulated upconversion luminescence: single particle vs. few-particle aggregates.

Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis

Inhibition of AMPK activation in Echinococcus granulosus sensu stricto limits the parasite’s glucose metabolism and survival

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein

Efficacy and Safety of Asparagusic Acid against Echinococcus multilocularis In Vitro and in a Murine Infection Model

Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond

Nrf2 induces angiogenesis in spinal cystic echinococcosis by activating autophagy via regulating oxidative stress

Transcriptome analysis uncovers the key pathways and candidate genes related to the treatment of Echinococcus granulosus protoscoleces with the repurposed drug pyronaridine

In Vitro Effects of Lonidamine and 6-Aminonicotinamide Against Echinococcus Granulosussensu Stricto and Echinococcus Multilocularis

Deprivation of L-Arginine Induces Oxidative Stress Mediated Apoptosis in Leishmania donovani Promastigotes: Contribution of the Polyamine Pathway

Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms

Ribonucleotide reductase as a therapeutic target for drug repurposing as anthelmintics

Investigation of the threonine metabolism of Echinococcus multilocularis: the threonine dehydrogenase as a potential drug target in alveolar echinococcosis

Advances in the pharmacological treatment of hepatic alveolar echinococcosis: From laboratory to clinic

Ghrelin regulating liver activity and its potential effects on liver fibrosis and Echinococcosis

In Vitro Efficacy of Ampelopsin Against Echinococcus Granulosus and Echinococcus Multilocularis

Digest the Sugar, Kill the Parasite: A New Experimental Concept in Treating Alveolar Echinococcosis

Repurposing of a library for high-content screening of inhibitors against Echinococcus granulosus

Improvement of Antialveolar echinococcosis efficacy of novel Albendazole-Bile acids Derivatives with Enhanced Oral Bioavailability

Anti-Inflammatory Responses Produced with Nippostrongylus brasiliensis-Derived Uridine via the Mitochondrial ATP-Sensitive Potassium Channel and Its Anti-Atherosclerosis Effect in an Apolipoprotein E Gene Knockout Mouse Model

Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model